BNP/CALL/MODERNA/100/0.1/17.01.25 | Delayed Deutsche Boerse AG 11:20:57 28/06/2024 BST | ||
| 3.18 EUR | +1.27% |
|
| Current month | -35.26% | ||
| 1 month | -54.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 3.18 | +1.27% |
| 27/06/24 | 3.14 | -3.68% |
| 26/06/24 | 3.26 | -24.71% |
| 25/06/24 | 4.33 | 0.00% |
| 24/06/24 | 4.33 | +5.10% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PN7FA9 |
| ISIN | DE000PN7FA93 |
| Date issued | 17/08/2023 |
| Strike | 100 $ |
| Maturity | 17/01/2025 (204 Days) |
| Parity | 10 : 1 |
| Emission price | 2.39 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.07 € |
|---|---|
| Lowest since issue | 0.84 € |
| Spread | 0.01 € |
| Spread % | 0.31% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.2
USD
Average target price
145.9
USD
Spread / Average Target
+20.36%
- Stock Market
- Warrants
- Warrant
